The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | Denosumab: the next big drug in myeloma?
Evangelos Terpos, MD, PhD, from the University of Athens, School of Medicine, Athens, Greece, discusses the results of a large multiple myeloma study comparing zoledronic acid and denosumab (NCT01345019) at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. This is one of the largest trials of this kind, with over 1700 patients enrolled. This was a randomised double-blind trial, where patients were also stratified regarding autologous transplantation, induction treatments, and the stage of the disease. No difference in overall survival was found between the two groups, however, there was increased progression free survival in the denosumab arm. Denosumab was also found to have a lower toxicity. Dr Terpos states that these findings show that denosumab could be licensed for use in clinical practice, and exciting new development.
